{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:41:47Z","timestamp":1788306107544,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008676","name":"CMC Microsystems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017317","name":"Catholic Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.pvr.2020.100203","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T22:45:45Z","timestamp":1594421145000},"page":"100203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up"],"prefix":"10.1016","volume":"10","author":[{"given":"Sven-Eric","family":"Olsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Alberto","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Cesar","family":"Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punnee","family":"Pitisuttithum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angels","family":"Ulied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Varman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edson Duarte","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daron","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pvr.2020.100203_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.pvr.2020.100203_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.pvr.2020.100203_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"13","key":"10.1016\/j.pvr.2020.100203_bib4","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"10108","key":"10.1016\/j.pvr.2020.100203_bib5","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pvr.2020.100203_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pvr.2020.100203_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.pvr.2020.100203_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12879-014-0551-y","article-title":"Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial","volume":"14","author":"Castellsagu\u00e9","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.pvr.2020.100203_bib9","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.pvr.2020.100203_bib10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/21645515.2015.1009819","article-title":"Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.pvr.2020.100203_bib11","author":"World Health Organization (WHO)"},{"issue":"6","key":"10.1016\/j.pvr.2020.100203_bib12","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3947","article-title":"4-Valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years","volume":"140","author":"Ferris","year":"2017","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.pvr.2020.100203_bib13","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.pvr.2020.100203_bib14","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4161\/hv.29205","article-title":"Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types","volume":"10","author":"Roberts","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.pvr.2020.100203_bib15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/CVI.00348-09","article-title":"Multiplexed serologic assay for nine anogenital human papillomavirus types","volume":"17","author":"Opalka","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"issue":"37","key":"10.1016\/j.pvr.2020.100203_bib16","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.pvr.2020.100203_bib17","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/JCM.00236-10","article-title":"Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay","volume":"49","author":"Else","year":"2011","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.pvr.2020.100203_bib18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1128\/JCM.00235-10","article-title":"Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection","volume":"49","author":"Roberts","year":"2011","journal-title":"J. Clin. Microbiol."},{"issue":"19","key":"10.1016\/j.pvr.2020.100203_bib19","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pvr.2020.100203_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cct.2015.02.009","article-title":"Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine","volume":"42","author":"Luxembourg","year":"2015","journal-title":"Contemp. Clin. Trials"},{"issue":"5","key":"10.1016\/j.pvr.2020.100203_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pvr.2020.100203_bib22","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.pvr.2020.100203_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nyg\u00e5rd","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"issue":"44","key":"10.1016\/j.pvr.2020.100203_bib24","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1016\/j.vaccine.2014.08.004","article-title":"Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18","volume":"32","author":"Brown","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2020.100203_bib25","doi-asserted-by":"crossref","first-page":"100401","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pvr.2020.100203_bib26","author":"World Health Organization (WHO)"},{"issue":"22","key":"10.1016\/j.pvr.2020.100203_bib27","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.pvr.2020.100203_bib28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA."},{"issue":"16","key":"10.1016\/j.pvr.2020.100203_bib29","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2017.1840","article-title":"Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 Years after 60 months","volume":"317","author":"Ogilvie","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.pvr.2020.100203_bib30","article-title":"Immunogenicity of 2 and 3 doses of the quadrivalent human papillomavirus vaccine up to 120 Months postvaccination: follow-up of a randomized clinical trial","author":"Donken","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pvr.2020.100203_bib31","article-title":"Comparison of 2-dose and 3-dose regimens of 9-valent HPV vaccine: results from a 3-year randomized immunogenicity trial","author":"Bornstein","year":"2018","journal-title":"European Research Organization on Genital Infection and Neoplasia"},{"issue":"22","key":"10.1016\/j.pvr.2020.100203_bib32","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.pvr.2020.100203_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pcl.2015.08.004","article-title":"Global delivery of human papillomavirus vaccines,","volume":"63","author":"Wigle","year":"2016","journal-title":"Pediatr. Clin. North Am."},{"issue":"4","key":"10.1016\/j.pvr.2020.100203_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.pvr.2020.100203_bib35","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV after introduction of the vaccination program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"issue":"10197","key":"10.1016\/j.pvr.2020.100203_bib36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pvr.2020.100203_bib37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/INF.0000000000000793","article-title":"An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015","volume":"34","author":"Vichnin","year":"2015","journal-title":"Pediatr. Infect Dis. J."},{"key":"10.1016\/j.pvr.2020.100203_bib38","author":"World Health Organization (WHO)"},{"issue":"6","key":"10.1016\/j.pvr.2020.100203_bib39","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1791","article-title":"Safety of the 9-valent human papillomavirus vaccine","volume":"144","author":"Shimabukuro","year":"2019","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.pvr.2020.100203_bib40","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1808","article-title":"Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine","volume":"144","author":"Donahue","year":"2019","journal-title":"Pediatrics"}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852120300215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852120300215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:03:57Z","timestamp":1762513437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852120300215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"alternative-id":["S2405852120300215"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2020.100203","relation":{},"ISSN":["2405-8521"],"issn-type":[{"value":"2405-8521","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2020.100203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100203"}}